OFF-X Translational Safety Intelligence

Integrated preclinical and clinical safety data intelligence for anticipating drug toxicity risks and competitive advantage.

Overview

OFF-X Translational Safety Intelligence, developed by Clarivate, is a unique translational tool designed to provide integrated preclinical and clinical safety intelligence for drug development professionals. It is built to help life sciences teams anticipate safety risks early and drive competitive value by combining drug and class toxicity data in a single, coherent platform.

OFF-X is positioned within the pharmacovigilance and drug safety workflow, serving researchers, safety scientists, and drug development teams who need to understand the translational safety profile of compounds across both preclinical and clinical stages. By integrating these two data dimensions, OFF-X enables users to make more informed decisions about candidate compounds and therapeutic classes.

Core Capabilities

Provides unique insights into drug and class toxicity by integrating preclinical and clinical safety data in a single platform
Supports translational safety intelligence, bridging the gap between animal study findings and human clinical outcomes
Enables anticipation of safety risks earlier in the drug development process
Delivers competitive intelligence value by contextualising a compound's safety profile within its broader therapeutic class

Key Use Cases

Pharmacovigilance and drug safety monitoring throughout the research and development lifecycle
Assessing and comparing toxicity profiles across drug classes to inform candidate selection
Supporting safety teams in identifying potential off-target risks before they emerge in clinical settings
Informing regulatory and development strategy with integrated, evidence-based safety data

OFF-X is part of the broader Clarivate life sciences and healthcare product portfolio, which includes tools such as Cortellis and MetaCore, and is accessible via the Clarivate product login portal. It is designed for organisations seeking to strengthen their translational safety capabilities and reduce attrition risk in drug development programmes.